Celestica Manufactures Ventilator Components for Medtronic in Response to the COVID-19 Pandemic
TORONTO, April 23, 2020 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced it is collaborating with Medtronic, one of the world’s largest medical technology, services and solutions companies, to produce subassemblies for Medtronic Puritan Bennett™ 980 (PB980) ventilators.
High-performance ventilators like the PB980 are primarily designed for critically ill patients in high acuity settings and play a crucial role in the management of patients with severe respiratory illness, such as COVID-19, who require assistance because they cannot breathe effectively. Production will begin this month.“We are committed to supporting Medtronic with critical manufacturing and supply chain support for high grade ventilators that are in urgent demand for COVID-19 patient care,” said Kevin Walsh, Vice President, HealthTech, Celestica. “This agreement takes our decade-long collaboration to the next level and is a reflection of the trust that Medtronic has placed in Celestica to help them meet unprecedented global demand in these challenging times.”Over nearly two decades of working with customers to enable high-reliability medical devices, Celestica has focused on quality and regulatory compliance, underpinned by its ISO 13485 certified network. Celestica’s collaboration with Medtronic is just one example of how the company is enabling its customers to increase production of critical medical devices and equipment to help improve the outcome for COVID-19 patients. Other examples include:Increasing production of a portable ultrasound device used by doctors to quickly perform lung scans of patients exhibiting symptoms of COVID-19.Scaling to meet increasing demand for automated blood analyzer devices used in the testing process for COVID-19.Adding additional capacity to support the immediate production for a range of products including respiratory monitors and diagnostic systems that will be delivered to hospitals and temporary medical facilities.About CelesticaCelestica enables the world’s best brands. Through our recognized customer-centric approach, we partner with leading companies in aerospace and defense, communications, enterprise, healthtech, industrial, capital equipment, and energy to deliver solutions for their most complex challenges. As a leader in design, manufacturing, hardware platform and supply chain solutions, Celestica brings global expertise and insight at every stage of product development – from the drawing board to full-scale production and after-market services. With talented teams across North America, Europe and Asia, we imagine, develop and deliver a better future with our customers.For further information on Celestica, visit www.celestica.com.Forward-Looking StatementsThis news release contains forward-looking statements related to our collaboration with Medtronic, the intention and timing to produce subassemblies for Medtronic for ventilators for COVID-19 patients, and our production of other COVID-19 related products. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For those statements, we claim the protection of the safe harbor for forward looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995, and applicable Canadian securities laws. Forward-looking statements are provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Forward-looking statements are not guarantees of future performance and are subject to risks that could cause actual results to differ materially from conclusions, forecasts or projections expressed in such statements, including, among others, risks relating to the duration and severity of the COVID-19 pandemic, the demand for related medical supplies, and our ability to increase production of the medical supplies and equipment described in this press release as intended, as well as the risks discussed in our various public filings at www.sedar.com and www.sec.gov, including in our most recent Management’s Discussion and Analysis of Financial Condition and Results of Operations, and our most recent Annual Report on Form 20-F filed with, and subsequent reports on Form 6-K furnished to, the U.S. Securities and Exchange Commission, and as applicable, the Canadian Securities Administrators. The forward-looking statements contained in this press release are based on various assumptions, many of which involve factors that are beyond our control. The material assumptions include those related to the following: our ability to produce the medical supplies and equipment described in this press release as intended; the level of demand for ventilators for COVID-19 patients from Medtronic, and the continued need for medical supplies and equipment to aid in the diagnosis and treatment of COVID-19. While management believes these assumptions to be reasonable under the current circumstances, they may prove to be inaccurate. Except as required by applicable law, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts: Celestica Global Communications: (416) 448-2200, Celestica Investor Relations: (416) 448-2211,